XTX Topco Ltd Acquires New Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

XTX Topco Ltd purchased a new position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 21,367 shares of the biotechnology company's stock, valued at approximately $352,000. XTX Topco Ltd owned approximately 0.15% of Anika Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Jane Street Group LLC grew its holdings in Anika Therapeutics by 54.1% during the 3rd quarter. Jane Street Group LLC now owns 24,351 shares of the biotechnology company's stock worth $601,000 after acquiring an additional 8,550 shares in the last quarter. Barclays PLC grew its stake in Anika Therapeutics by 66.6% in the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company's stock worth $806,000 after purchasing an additional 13,054 shares in the last quarter. Wellington Management Group LLP increased its holdings in Anika Therapeutics by 3.7% in the fourth quarter. Wellington Management Group LLP now owns 39,785 shares of the biotechnology company's stock valued at $655,000 after buying an additional 1,407 shares during the last quarter. American Century Companies Inc. raised its stake in Anika Therapeutics by 9.3% during the fourth quarter. American Century Companies Inc. now owns 29,891 shares of the biotechnology company's stock valued at $492,000 after buying an additional 2,553 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Anika Therapeutics by 20.8% during the 4th quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company's stock worth $832,000 after buying an additional 8,711 shares during the last quarter. Institutional investors own 91.53% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ANIK shares. B. Riley assumed coverage on Anika Therapeutics in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Barrington Research lowered their target price on shares of Anika Therapeutics from $25.00 to $20.00 and set an "outperform" rating for the company in a research note on Thursday, March 13th. Finally, StockNews.com upgraded shares of Anika Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th.

Anika Therapeutics Price Performance

Shares of NASDAQ ANIK traded up $0.05 during mid-day trading on Friday, hitting $14.43. The company had a trading volume of 25,955 shares, compared to its average volume of 69,656. The stock has a market cap of $204.56 million, a price-to-earnings ratio of -2.17 and a beta of 0.82. The firm's 50 day simple moving average is $15.44 and its two-hundred day simple moving average is $17.23. Anika Therapeutics, Inc. has a 12 month low of $12.83 and a 12 month high of $29.12.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last posted its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.13). The company had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. Equities analysts forecast that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current year.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.